What it is
Intrahepatic cholestasis of pregnancy (ICP), sometimes called obstetric cholestasis, is a temporary liver condition unique to pregnancy. Pregnancy hormones slow the flow of bile from the liver, and bile acids spill into the bloodstream. The classic symptom is relentless itching — often worst at night and on the palms and soles — usually without a rash. Diagnosis is confirmed by a fasting serum bile acid level (and sometimes liver function tests). ICP is important because higher bile acid levels are associated with an increased risk of stillbirth, and delivery timing is the main tool clinicians have to reduce that risk. Symptoms and lab values typically resolve within days to weeks after birth, but ICP can recur in future pregnancies and is associated with a higher long-term risk of liver and gallbladder disease.
Evidence review links
Each link opens the full review on the publisher's site in a new tab.
- Ovadia et al. — Association of adverse perinatal outcomes with total bile acid concentration in ICP: individual-patient data meta-analysisThe Lancet (2019)
- PITCHES trial — Ursodeoxycholic acid versus placebo in women with ICP (Chappell et al.)The Lancet (2019)
- SMFM Consult Series #53: Intrahepatic Cholestasis of PregnancySociety for Maternal-Fetal Medicine (2021)
- Green-top Guideline No. 43: Intrahepatic Cholestasis of PregnancyRCOG (2022)
- ICP Care — Patient education and supportICP Care
- Evidence on: Cholestasis of PregnancyEvidence Based Birth
Possible benefits
- Diagnosis is straightforward once suspected — a bile acid blood test confirms itReview sources ↓
- Ursodeoxycholic acid (UDCA / ursodiol) often reduces itching and modestly lowers bile acidsReview sources ↓
- Planned delivery timing based on peak bile acid levels reduces the risk of late-pregnancy stillbirthReview sources ↓
- Symptoms usually resolve within 2–4 weeks postpartumReview sources ↓
Possible risks
- Increased risk of stillbirth, especially when peak bile acids are ≥100 µmol/L (SMFM 2021; Ovadia et al. 2019, Lancet)Review sources ↓
- Higher rates of preterm birth (spontaneous and iatrogenic), meconium-stained fluid, and NICU admissionReview sources ↓
- Severe, sleep-disrupting itching that can affect mental healthReview sources ↓
- Recurrence in ~60–70% of future pregnancies; long-term association with hepatobiliary diseaseReview sources ↓
- UDCA reduces itching but has not been shown in the PITCHES trial (2019) to reduce stillbirth on its own — delivery timing remains the primary risk-reduction toolReview sources ↓
Alternatives
- Watchful waiting is not appropriate once ICP is diagnosed — active monitoring and a delivery plan are standardReview sources ↓
- For itching relief: cool baths, cotton clothing, aqueous cream with menthol, antihistamines at night (comfort only, not disease-modifying)Review sources ↓
- Rifampicin as an add-on to UDCA in severe/refractory cases (specialist decision)Review sources ↓
- Individualized delivery timing (typically 36–37 weeks for severe ICP with bile acids ≥100, 37–38 weeks for moderate, 38–39 weeks for mild) — per SMFM and RCOG guidanceReview sources ↓
Current evidence
The largest evidence base is Ovadia et al. (Lancet 2019), an individual-patient-data meta-analysis of ~5,500 ICP pregnancies showing stillbirth risk rises sharply once total bile acids reach ≥100 µmol/L. The PITCHES RCT (Chappell et al., Lancet 2019) found that UDCA improved itching but did not significantly reduce a composite adverse perinatal outcome, which reframed UDCA as symptom-directed rather than life-saving. SMFM Consult Series #53 (2021) and RCOG Green-top Guideline No. 43 (2022) both recommend bile-acid-guided delivery timing, active fetal surveillance, and UDCA for symptom control. ICP Care and Evidence Based Birth have plain-language summaries that mirror this guidance. Guideline differences: some centers offer delivery earlier for bile acids ≥40, while others reserve early delivery for ≥100 — ask your team where they draw the line and why.
Where the evidence is clear · where people may choose differently
For most topics, guidelines from ACOG, WHO, and other major bodies broadly agree on the core safety points (when to act in an emergency, informed-consent standards, monitoring baselines). Where reasonable people — and even guidelines — differ tends to be around thresholds (when to start or stop something), preferences (comfort, environment, support), and values (how you weigh small risks against benefits). Use the questions below to explore those pieces with your care team.
Educational only. Your care team can help you weigh what applies to your specific situation.
Related evidence topics
- Induction of LaborMedical methods used to start labor before it begins on its own — see the method-specific topics below for details.
- Informed Consent & RefusalYour right to information about, and to accept or decline, any proposed care.
- Fetal MonitoringContinuous vs intermittent monitoring of the baby's heart rate during labor.
Questions to ask your care team
- ?What is my total bile acid level, and when will it be rechecked?
- ?Based on my numbers, what delivery timing are you recommending, and what guideline is that from (SMFM, RCOG, ACOG)?
- ?Are you offering ursodeoxycholic acid (UDCA)? What are the goals — itching relief, bile acid reduction, or both?
- ?What fetal monitoring plan do you recommend between now and delivery (NST, BPP, kick counts)?
- ?What symptoms should make me call immediately or come in (right upper quadrant pain, jaundice, dark urine, reduced fetal movement)?
- ?Will you check my liver function and bile acids postpartum to confirm resolution?
- ?What are my options for induction versus scheduled cesarean, and what's the reasoning for the timing you're suggesting?
- ?How does this affect breastfeeding, contraception choices (especially estrogen), and future pregnancies?
Universal questions (works for any decision)
A short BRAIN-style set you can bring to any conversation about interventions, monitoring, or care decisions.
- ?Why are you recommending this now — is it urgent, routine, or optional?
- ?What happens if we wait an hour (or longer) before deciding?
- ?What signs would tell us this is working — or that we need to change course?
- ?What are the alternatives, including doing nothing?
- ?What would you recommend if this were your family?
- ?What would change your recommendation?
Sources & provenance
Tap a source to open the original guideline or review in a new tab.
- Ovadia et al. — Association of adverse perinatal outcomes with total bile acid concentration in ICP: individual-patient data meta-analysis — The Lancet (2019)
- PITCHES trial — Ursodeoxycholic acid versus placebo in women with ICP (Chappell et al.) — The Lancet (2019)
- SMFM Consult Series #53: Intrahepatic Cholestasis of Pregnancy — Society for Maternal-Fetal Medicine (2021)
- Green-top Guideline No. 43: Intrahepatic Cholestasis of Pregnancy — RCOG (2022)
- ICP Care — Patient education and support — ICP Care
- Evidence on: Cholestasis of Pregnancy — Evidence Based Birth
Plain-language paraphrase from published trials and guidelines. No verbatim excerpts. Editors should re-verify bile-acid thresholds and delivery-timing recommendations against the most recent SMFM/RCOG/ACOG guidance before publish, as thresholds have shifted over time.
Last reviewed: 2026-07-28
Further reading — canonical references
Read the source material directly. Each link opens the publisher's own current guidance in a new tab — cross-check what we summarize against what they say.
Tier 1 · Clinical guidelines
Tier 2 · Systematic reviews
Educational only. Guidelines evolve — the linked publisher pages will reflect newer guidance than any static snapshot.
Version history — v1.0.0
v1.0.0 · 2026-07-28 · LlaMamma editors
Initial cholestasis (ICP) topic covering bile acids, delivery timing, UDCA evidence, and questions for the care team.
Sources: Ovadia et al. Lancet 2019; PITCHES trial Lancet 2019; SMFM Consult Series #53 (2021); RCOG Green-top Guideline No. 43 (2022)
New guidance from ACOG, WHO, Evidence Based Birth, or other listed sources is recorded here and can be updated remotely without a new app release.
